News

Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADA Advancing Precision Diabetes Medicine Symposium


Posted on October 7, 2019 by


New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain.  The GlycoMark test, an FDA-cleared and CE marked blood test used…
Read More

New Clinical Study Data Show the GlycoMark® Test Helps Confirm Compliance and Appropriate Response to SGLT-2 Inhibitors


Posted on June 13, 2019 by


New York, NY (June 13, 2019)— GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to…
Read More

New Data on the GlycoMark® Test In Patients Taking SGLT-2 Inhibitors To Be Presented at the American Diabetes Association 79th Scientific Sessions


Posted on June 4, 2019 by


New York, NY (June 4, 2019) — GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco.  The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients…
Read More